Oil prices hold sharp losses with focus on secondary India tariffs
Daxor Corporation (NASDAQ:DXR), a healthcare company with a market capitalization of $48.5 million and an overall "GOOD" financial health rating according to InvestingPro, held its annual meeting of shareholders on June 24, 2025, according to a press release statement based on a recent SEC filing. At the meeting, shareholders elected six directors to serve terms expiring at the next annual meeting.
The directors elected were Henry D. Cremisi, MD; Edward Feuer; Joy Goudie, Esq.; Michael Feldschuh; Jonathan Feldschuh; and Caleb DesRosiers, Esq. Each nominee received between 3,473,576 and 3,493,651 votes in favor, with withheld votes ranging from 1,899 to 21,974.
In addition to the election of directors, shareholders voted on the ratification of the company’s independent registered public accounting firm. Bush & Associates, CPA, was ratified as Daxor’s auditor for the coming year, with 3,494,574 votes in favor, 100 votes against, and 876 abstentions.
The company’s common stock trades on the Nasdaq under the symbol DXR.
All information in this article is based on a press release statement and details from the company’s SEC filing.
In other recent news, Daxor Corporation has submitted its latest blood volume analyzer, the Daxor BVA, to the FDA. This new device is designed to improve fluid management in healthcare settings by providing rapid and precise blood volume analysis. Developed under a U.S. Department of Defense contract, the Daxor BVA system offers a processing time three times faster than its predecessor, the BVA-100™, along with enhanced portability and point-of-care capabilities. These advancements are expected to integrate sophisticated blood volume diagnostics into routine clinical practices effectively. In addition, Daxor’s Blood Volume Analyzer (BVA-100®) garnered significant attention at the American College of Cardiology’s 74th Annual Scientific Session and Expo. Dr. Marat Fudim of Duke University Health presented research highlighting the superiority of BVA over traditional pressure-based assessments for heart failure patients. The research underscores the importance of volume management over pressure management in treating heart failure, emphasizing the need for precise congestion management. Daxor continues to support ongoing trials in heart failure treatment with NIH backing and is collaborating with the U.S. Department of Defense to develop analyzers for combat casualty care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.